文献速递中医内科中药与中成药合理使用

五味苦参肠溶胶囊通过抑制NLRP3炎症小体与STAT3通路缓解DSS诱导小鼠结肠炎

Wuwei Kushen Changrong capsule alleviates DSS-induced colitis in mice via inhibition of NLRP3 inflammasome and STAT3 pathway.
PubMed 文献 · Front Pharmacol · 2024-09-12

本研究在小鼠3% DSS诱导溃疡性结肠炎模型中评价五味苦参肠溶胶囊(CSCC)的抗结肠炎作用及机制。结果显示CSCC上调Gpr43、促进ZO-1和Occludin紧密连接蛋白表达,抑制MEK4/JNK1/STAT3活化及STAT3/NLRP3/IL-1β通路,减少IL-17A等炎症因子产生,保护肠道屏障。

要点

  • CSCC可上调Gpr43并促进ZO-1、Occludin表达以保护肠道屏障。
  • CSCC抑制MEK4/JNK1/STAT3及STAT3/NLRP3/IL-1β通路。
  • CSCC减少IL-17A等炎症因子产生,减轻DSS诱导结肠炎。

核心结论

  • CSCC保护DSS诱导结肠炎的机制可能包括上调Gpr43、抑制STAT3/NLRP3通路及抑制IL-17A等炎症因子。
  • 研究提示CSCC有潜力作为管理UC进展的治疗候选药物。

研究设计与样本

  • 研究采用3% DSS诱导的小鼠溃疡性结肠炎模型评价CSCC的保护作用。
  • 评估指标包括体重、疾病活动指数(DAI)评分、结肠长度和组织病理学评分。
  • 采用免疫组化、免疫荧光、ELISA和实时荧光定量PCR(RT-PCR)评估结肠组织、细胞功能及免疫炎症状态。
  • 采用Western blot测定相关通路和受体的蛋白表达水平,所有实验均重复进行。

主要发现

  • CSCC通过上调Gpr43、促进ZO-1和Occludin紧密连接蛋白表达保护小鼠免受DSS诱导结肠炎。
  • CSCC抑制MEK4/JNK1/STAT3激活通路,进而抑制STAT3/NLRP3/IL-1β通路。
  • CSCC抑制IL-17A等炎症因子的产生。

临床怎么用

  • 本研究为动物实验机制探讨,提示CSCC可能通过调控Gpr43-STAT3/NLRP3轴保护肠道屏障。
  • 结果支持CSCC作为UC治疗候选药物的潜力,但临床转化需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Wuwei Kushen Changrong capsule (Composite Sophora Colon-soluble Capsule, CSCC) is a Chinese patent medicine developed to treat ulcerative colitis. Studies highlight CSCC potential efficacy for ulcerative colitis (UC) but unclear mechanism limits its widely treatment for patients. We aimed to investigate the anti-colitis efficacy of CSCC and explore the mechanism by which GPR43 inhibits the NLRP3/STAT3 signaling pathway, thereby mediating the protective effects of CSCC on the intestinal barrier. METHODS: The protective effects of CSCC were evaluated in a murine ulcerative colitis model induced by 3% DSS. Assessments included body weight, Disease Activity Index (DAI) score, colon length, and histopathological score. Colon tissue, cell function, and immune-inflammatory status were evaluated using immunohistochemistry, immunofluorescence, ELISA, and real-time fluorescence quantitative PCR (RT-PCR). Protein expression levels of relevant pathways and receptors were measured using Western blot. All experiments were repeated. RESULTS: CSCC protected mice from DSS-induced colitis by upregulating Gpr43, promoting the expression of ZO-1 and Occludin tight junction proteins. Mechanistically, CSCC inhibits the MEK4/JNK1/STAT3 activation pathway, consequently suppressing the STAT3/NLRP3/IL-1β pathway and inhibiting the production of inflammatory factors such as IL-17A. CONCLUSION: The mechanisms through which CSCC protects against DSS-induced colitis may include upregulating Gpr43, inhibiting the STAT3/NLRP3 pathway, and suppressing inflammation factors like IL-17A. These findings highlight the mechanisms underlying CSCC's anti-colitis effects and suggest its potential as a therapeutic candidate for managing the progression of UC.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen M, Feng Y, Luo D, et al. Wuwei Kushen Changrong capsule alleviates DSS-induced colitis in mice via inhibition of NLRP3 inflammasome and STAT3 pathway. Front Pharmacol. 2024. PMID: 39329121. doi:10.3389/fphar.2024.1423012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。